Autobio(SH:603658) Xin Lang Zheng Quan·2025-09-23 01:23Core Viewpoint - Antu Biology's stock performance shows a slight decline, with a trading volume of 1.01 billion yuan and a net financing purchase indicating low investor confidence [1][2]. Financing Summary - On September 22, Antu Biology had a financing purchase of 10.57 million yuan and a net financing purchase of 3.90 million yuan, with a total financing balance of 622 million yuan, representing 2.72% of its market capitalization [1]. - The financing balance is below the 50th percentile level over the past year, indicating a low position [1]. - The short selling data shows a repayment of 100 shares with no shares sold, and a short selling balance of 1.81 million yuan, also below the 10th percentile level over the past year [1]. Financial Performance - For the first half of 2025, Antu Biology reported a revenue of 2.06 billion yuan, a year-on-year decrease of 6.65%, and a net profit of 571 million yuan, down 7.83% year-on-year [2]. - Cumulatively, the company has distributed 4.046 billion yuan in dividends since its A-share listing, with 1.794 billion yuan distributed in the last three years [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 34,200, with an average of 16,719 circulating shares per person, a slight decrease of 0.04% [2]. - The top ten circulating shareholders include notable institutional investors, with changes in holdings indicating varying levels of confidence among investors [3].